<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30338462</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>19</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1932-2267</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>18</Day>                    </PubDate>                </JournalIssue>                <Title>Journal of cancer survivorship : research and practice</Title>                <ISOAbbreviation>J Cancer Surviv</ISOAbbreviation>            </Journal>            <ArticleTitle>Patterns of medication adherence in a multi-ethnic cohort of prevalent statin users diagnosed with breast, prostate, or colorectal cancer.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s11764-018-0716-6</ELocationID>            <Abstract>                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To investigate the implications of a cancer diagnosis on medication adherence for pre-existing comorbid conditions, we explored statin adherence patterns prior to and following a new diagnosis of breast, colorectal, or prostate cancer among a multi-ethnic cohort.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">We identified adults enrolled at Kaiser Permanente Northern California who were prevalent statin medication users, newly diagnosed with breast, colorectal, or prostate cancer between 2000 and 2012. Statin adherence was measured using the proportion of days covered (PDC) during the 2-year pre-cancer diagnosis and the 2-year post-cancer diagnosis. Adherence patterns were assessed using generalized estimating equations, for all cancers combined and stratified by cancer type and race/ethnicity, adjusted for demographic, clinical, and tumor characteristics.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 10,177 cancer patients, statin adherence decreased from pre- to post-cancer diagnosis (adjusted odds ratio (OR<sub>adj</sub>):0.91, 95% confidence interval (95% CI):0.88-0.94). Statin adherence decreased from pre- to post-cancer diagnosis among breast (OR<sub>adj</sub>:0.94, 95% CI:0.90-0.99) and colorectal (OR<sub>adj</sub>:0.79, 95% CI:0.74-0.85) cancer patients. No difference in adherence was observed among prostate cancer patients (OR<sub>adj</sub>:1.01, 95% CI:0.97-1.05). Prior to cancer diagnosis, adherence to statins was generally higher among non-Hispanic whites and multi-race patients than other groups. However, statin adherence after diagnosis decreased only among these two populations (OR<sub>adj</sub>:0.85, 95% CI:0.85-0.92 and OR<sub>adj</sub>:0.86, 95% CI:0.76-0.97), respectively.</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We found substantial variation in statin medication adherence following diagnosis by cancer type and race/ethnicity among a large cohort of prevalent statin users in an integrated health care setting.</AbstractText>                <AbstractText Label="IMPLICATIONS FOR CANCER SURVIVORS" NlmCategory="CONCLUSIONS">Improving our understanding of comorbidity management and polypharmacy across diverse cancer patient populations is warranted to develop tailored interventions that improve medication adherence and reduce disparities in health outcomes.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Banegas</LastName>                    <ForeName>Matthew P</ForeName>                    <Initials>MP</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-6158-7162</Identifier>                    <AffiliationInfo>                        <Affiliation>Center for Health Research, Kaiser Permanente Northwest, 3800 N. Interstate Ave, Portland, OR, 97227-1110, USA. Matthew.P.Banegas@kpchr.org.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Emerson</LastName>                    <ForeName>Marc A</ForeName>                    <Initials>MA</Initials>                    <AffiliationInfo>                        <Affiliation>Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Adams</LastName>                    <ForeName>Alyce S</ForeName>                    <Initials>AS</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Research, Kaiser Permanente, Oakland, CA, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Achacoso</LastName>                    <ForeName>Ninah S</ForeName>                    <Initials>NS</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Research, Kaiser Permanente, Oakland, CA, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Chawla</LastName>                    <ForeName>Neetu</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Research, Kaiser Permanente, Oakland, CA, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Alexeeff</LastName>                    <ForeName>Stacey</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Research, Kaiser Permanente, Oakland, CA, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Habel</LastName>                    <ForeName>Laurel A</ForeName>                    <Initials>LA</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Research, Kaiser Permanente, Oakland, CA, USA.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>R01 CA098838</GrantID>                    <Agency>National Cancer Institute</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>R01AG032249</GrantID>                    <Agency>National Cancer Institute</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>U24 CA1715</GrantID>                    <Agency>National Cancer Institute</Agency>                    <Country/>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>18</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>J Cancer Surviv</MedlineTA>            <NlmUniqueID>101307557</NlmUniqueID>            <ISSNLinking>1932-2259</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Adherence</Keyword>            <Keyword MajorTopicYN="N">Breast cancer</Keyword>            <Keyword MajorTopicYN="N">Colorectal cancer</Keyword>            <Keyword MajorTopicYN="N">Comorbidities</Keyword>            <Keyword MajorTopicYN="N">Prostate cancer</Keyword>            <Keyword MajorTopicYN="N">Race/ethnicity</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>02</Month>                <Day>17</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>11</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>20</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>20</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>20</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30338462</ArticleId>            <ArticleId IdType="doi">10.1007/s11764-018-0716-6</ArticleId>            <ArticleId IdType="pii">10.1007/s11764-018-0716-6</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>